Alexion Pharmaceuticals

Phone: +1 475-230-2596

Fax: +1 (203) 271 8189

Web: https://alexion.com

Type	Subsidiary
Traded as	Nasdaq: ALXN
Industry	Pharmaceutical industry
Founded	1992 (1992)
Founder	Leonard Bell
Headquarters	Boston, Massachusetts, U.S.
Key people	Leonard Bell (Chairman) Ludwig N. Hantson (CEO)
Products	Eculizumab (Soliris) Ravulizumab (Ultomiris) Asfotase alfa (Strensiq) Sebelipase alfa (Kanuma) Andexanet alfa (Andexxa)
Revenue	US$6.069 billion (2020)
Net income	US$603 million (2020)
Total assets	US$18.103 billion (2020)
Total equity	US$11.651 billion (2020)
Number of employees	2,525 (2020)
Parent	AstraZeneca
Website	www.alexion.com

People living with rare and devastating diseases are our Guiding Star. We believe it is our responsibility to listen to, understand, and change the lives of patients and those who work tirelessly to help them. To transform the lives of people affected by rare diseases and devastating conditions by continuously innovating and creating meaningful value in all that we do. And we’re making real progress, every day. We continue to deepen our understanding of rare disease, which began with our pioneering work in complement biology. This knowledge allows us to innovate and evolve into new areas, where there is great unmet need and opportunity to help patients and families fully live their best lives. We’ve delivered transformative medicines for people with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD), generalized Myasthenia Gravis (gMG), hypophosphatasia (HPP), and lysosomal acid lipase deficiency (LAL-D). We invest in and value people who believe in the importance of our purpose and understand what it takes to deliver on it. Our culture is rooted in integrity, inclusiveness, and our dedication to joining and supporting the communities in which we live and work. At Alexion, our passion drives us to continuously innovate and create meaningful value in all we do. In doing so, we change lives for the better – ours, people living with rare diseases, and the communities we serve. Every day.

For detailed contact information visit location pages below.